Join PACT and our proud sponsor RSM (in person) for a life sciences roundtable exclusive to life sciences executives and investors. Topics to be discussed are:
Moderator:
Michael Romano, Partner, RSM
Speakers:
Andrew Steinsapir, Gene Therapy Program Lead, Deerfield Management
Audrey Greenberg, Co-Founder, Center for Breakthrough Medicines
David Greenwald, Ph.D., Vice President, Business Development- Therapeutics group, Deerfield Management
Scott Snyder PhD, Chief Digital Officer, Eversana
Steven Kelly, President and Chief Executive Officer, Carisma Therapeutics
Thank you to our sponsor:
RSM
COVID protocols
Per RSM policy, all attendees of RSM-sponsored in-person events must be vaccinated against COVID-19 or have recently tested negative. RSM will follow any additional local, host or venue specific COVID protocols regarding vaccination, testing, social distancing and mask wearing.
About the speakers:
Michael Romano is the northeast leader of the Finance and Accounting Outsourcing consulting practice and national co-leader of the life sciences Biopharma Industry practice group. Michael has over 25 years of diverse experience in both the life sciences industry and as an audit, tax, and business consultant; having started his career with a Big Four accounting firm. Michael brings diverse industry experience specific to the life sciences services industry. In this capacity, Michael has specific experience in general management, financial management, M&A and global operations. He has orchestrated successful financial and operational turnarounds, restructured and reorganized businesses and executed growth strategies.
As a leader in the Managed Technology Services practice group, Michael serves his clients in a consulting capacity offering finance and accounting outsourcing and CFO advisory services to emerging growth and mid-market companies. In this capacity, Michael assists clients with their accounting and financial reporting requirements along with special projects involving capital raises, M&A, carve-outs, finance transformation, and providing leadership and financial guidance to execute initiatives for growth.
Andrew Steinsapir is Gene Therapy Program Lead, Deerfield Discovery and Development, and joined Deerfield in 2021. Prior to Deerfield, Mr. Steinsapir was a Consultant for over three years at Dark Horse Consulting Group, where he provided strategic and tactical support for more than 30 cell and gene therapy firms, pharma, and investment firms. Previous to Dark Horse, Mr. Steinsapir worked at 4D Molecular Therapeutics for over three years, holding various positions, with his most recent role being Senior Process Development Associate I. Mr. Steinsapir holds a B.S. in Chemical Engineering with an emphasis on Biotechnology from the University of California, Berkeley.
Audrey Greenberg is Co-founder of the Center for Breakthrough Medicines (CBM) and Discovery Labs (DL). CBM is a pharma services organization enabling the rapid development and commercialization of advanced therapies and is based at DL, a 3 million square foot integrated life sciences ecosystem. Audrey is responsible for strategic direction and execution, team attraction and management and joint venture and investor relationships.
Audrey is a member of the Board of Directors for New York Mortgage Trust (NASDAQ: NYMT), The Greater Philadelphia Chamber of Commerce and the King of Prussia Business District. She is an active participant in the Chamber’s Diverse Procurement Collaborative, Philadelphia Skills Forward Initiative, and the CEO Council for Growth’s Cell and Gene Therapy and Connected Health Initiative.
Audrey is a fierce advocate for the global recognition of Greater Philadelphia as the number one location for Cell and Gene Therapy. She has spoken at over 100 conferences and panels over the last 12 months passionately promoting “Cellicon Valley” and speaking as a subject matter expert in building bioinnovation hubs.
David Greenwald, Ph.D., is Vice President, Business Development on the Therapeutics group and joined the Firm in 2018. In this role, Dr. Greenwald is responsible for searching for new investment opportunities, supporting business development of Deerfield private portfolio companies, and providing his expertise to Deerfield’s research collaborations and venture creation efforts. Prior to joining Deerfield, Dr. Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures. He was a co-founder and Chief Executive Officer of Relay Technology Management, Inc. and a co-inventor of the Relay Innovation Engine software platform. After Relay was acquired by Decision Resources Group, Dr. Greenwald served as the Director of Client Solutions at Decision Resources Group. Before that, he was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked on developing diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his Ph.D. in Genetics from Tufts University. Dr. Greenwald currently serves on the Boards of Jaguar Gene Therapy, Axovia Therapeutics, and Apertura Gene Therapy.
Dr. Snyder is a recognized thought leader in technology and innovation. He has more than 30 years of experience in emerging technologies, business strategy and innovation, and digital transformation for Global 1000 companies and startup ventures. He is the co-author of Goliath’s Revenge: How Established Companies Turn the Tables on Digital Disruptors and the author of The New World of Wireless: How to Compete in the 4G Revolution and numerous other articles on emerging technologies and innovation.
Dr. Snyder is currently the Chief Digital Officer of EVERSANA focused on accelerating the life sciences commercialization model. Dr. Snyder was recently the Global Head of Digital and Innovation at Heidrick Consulting. Before Heidrick, he was the Chief Technology and Innovation Officer at Safeguard Scientifics which provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Prior to Safeguard, Dr. Snyder was the Co-Founder, President and Chief Strategy Officer at Mobiquity (recently acquired by Hexaware), a leader in delivering innovative mobile and digital solutions for enterprises. Dr. Snyder has also held executive positions with several Fortune 500 companies including GE and Lockheed Martin, has been the CEO of a leading strategic planning firm, Decision Strategies International (now part of Heidrick & Struggles), and has also started business ventures in software including OmniChoice, a CRM/Analytics applications provider.
Dr. Snyder is a Senior Fellow in the Management Department at the Wharton School, an Adjunct Faculty Member in the School of Engineering and Applied Science at the University of Pennsylvania, and has lectured at MIT, Babson, Duke, Georgia Tech and INSEAD on Digital Innovation, Decision-making, Business and IT Strategy, Emerging Technologies, Product Design and Development, and Big Data/Analytics. Dr. Snyder is a Digital Economy Project Fellow for the World Economic Forum and sits on the Penn Health Tech Advisory Board. He also holds three patents for personalization engines and has been quoted as a thought leader in numerous publications including CIO Magazine, WIRED, Forbes, Knowledge@Wharton, Los Angeles Times, The Wall Street Journal, CNBC, and the Financial Times.
Dr. Snyder earned his B.S., M.S., and Ph.D. in Systems Engineering from University of Pennsylvania
Steven Kelly joined Carisma Therapeutics in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Prior to joining Carisma, Mr. Kelly held a number of leadership positions in the biotechnology industry including: CEO, Pinteon Therapeutics; CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.
Steve holds a BS from the University of Oregon and an MBA from Cornell University.
Have a login? Login Now
{{vm.loginInfo.errorMessage}}
Create an Account
Forgot your Username or Password?
Register as Guest
Address
Phone
{{slot.Name}}
{{ vm.EventInfo.EventSettings.NoShowPolicy }}